Meeting
2023 ASCO Annual Meeting
Phase Ib study of talimogene laherparepvec (T-VEC) in combination with chemotherapy (CT) or endocrine therapy (ET) in patients with metastatic, unresectable, or locoregionally recurrent HER2-negative breast cancer (BC).
Authors
Laura Ann Huppert
University of California, San Francisco, San Francisco, CA
Laura Ann Huppert , Amelia S Gliwa , Madeline Tait , Laura Quintal , Stephanie Starzinski , Alexander Cheung , Mark M. Moasser , Melanie Majure , Michelle E. Melisko , Hope S. Rugo , Pamela N. Munster , Michael J. Campbell , Lawrence Fong , Amy Jo Chien
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Clinical Trial Registration Number
NCT03554044
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1091)
DOI
10.1200/JCO.2023.41.16_suppl.1091
Abstract #
1091
Poster Bd #
312
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
IMpassion132: A double-blind randomized phase 3 trial evaluating chemotherapy (CT) ± atezolizumab (atezo) for early progressing locally advanced/metastatic triple-negative breast cancer (mTNBC).
First Author: Rebecca Dent
Poster
2023 ASCO Annual Meeting
Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.
First Author: Nagi S. El Saghir
Poster
2023 ASCO Annual Meeting
A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101.
First Author: Yelena Y. Janjigian
Poster
2022 ASCO Gastrointestinal Cancers Symposium
NeoOPTIMIZE: An open-label, phase II trial and biomarker discovery platform to assess the efficacy of adaptive switching of modified FOLFIRINOX (mFFX) or gemcitabine/nab-paclitaxel (GA) as a neoadjuvant strategy for patients with resectable/borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).
First Author: Charles D. Lopez